Survodutide 10mg
$80.00
In stock
Product Details
Survodutide (formerly BI 456906), developed by Boehringer Ingelheim, is an investigational, long-acting dual agonist targeting both glucagon and GLP-1 receptors, designed for once-weekly subcutaneous administration. By simultaneously influencing energy intake and energy expenditure, this dual-receptor approach has the potential to deliver greater weight loss compared to traditional GLP-1–only therapies—while maintaining comparable glycemic control and offering additional, direct benefits to liver function.
The compound is strategically engineered with a preferential bias toward GLP-1 receptor activity, maximizing its well-established effects on appetite regulation and blood sugar control. At the same time, it harnesses the metabolic actions of glucagon, particularly in the liver, to further support fat metabolism and overall metabolic health.
Survodutide 10mg
